The Shanghai Institute of Biological Sciences (SIBS) has won SFDA approval to produce its single-dose vaccine for H1N1 swine flu. The Institute expects to produce 3 million doses of the vaccine by October 1 and 10 million doses by year end. SIBS is the third China entity to be given approval for a swine flu vaccine; the other two are Sinovac Biotech (北京科兴生物制品有限公司) and Hualan Biological Engineering Inc. More details...

Stock Symbol: (NYSE Amex: SVA)